Assembly Biosciences, Inc.
ASMB
Rank in Stocks
#12736
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development... Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Share Price
$21.79
Last synced: 2026-11-09
Market Cap
$443.66M
Change (1 day)
6.71%
Change (1 year)
-34.23%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Assembly Biosciences, Inc. (ASMB)
Category
Healthcare
EPS for Assembly Biosciences, Inc. (ASMB)
EPS as of June 2026 TTM: $0.55
According to Assembly Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $0.55. At the end of 2025 the company had an EPS of $-0.55, an increase over its 2024 EPS of $-6.69.
EPS history for Assembly Biosciences, Inc. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.55 | -200.00% |
| 2025 | $-0.55 | -91.78% |
| 2024 | $-6.69 | -50.00% |
| 2023 | $-13.38 | -41.37% |
| 2022 | $-22.82 | -36.61% |
| 2021 | $-36.00 | 140.00% |
| 2020 | $-15.00 | -46.04% |
| 2019 | $-27.80 | -30.15% |
| 2018 | $-39.80 | 65.15% |
| 2017 | $-24.10 | -6.23% |
| 2016 | $-25.70 | 41.99% |
| 2015 | $-18.10 | -46.76% |
| 2014 | $-34.00 | -32.00% |
| 2013 | $-50.00 | -48.67% |
| 2012 | $-97.40 | -45.46% |
| 2011 | $-178.60 | 44.81% |
| 2010 | $-123.33 | 141.82% |
| 2009 | $-51.00 | -51.04% |
| 2008 | $-104.17 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 2,747.27% |
US
|
|
| $-7.07 | -1,385.45% |
US
|
|
| $-5.29 | -1,061.82% |
AU
|
|
| $12.88 | 2,241.84% |
BE
|
|
| $21.56 | 3,820.00% |
NL
|
Questions about Assembly Biosciences, Inc.'s earnings per share (EPS)
What is Assembly Biosciences, Inc.'s earnings per share (EPS)?
Assembly Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $0.55, as of Jun 2026.
What was Assembly Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Assembly Biosciences, Inc.'s earnings per share (EPS) was $-0.55, compared with $-6.69 in 2024.
How has Assembly Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Assembly Biosciences, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.55) and lowest in 2021 ($-36.00).
How does Assembly Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Assembly Biosciences, Inc.'s earnings per share (EPS) ($0.55) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.